Charles L. Daley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Charles L. Daley has a total of 713 co-authors. Here are the top co-authors by number of shared publications:
David E Griffith
National Jewish Health and the University of Colorado School of Medicine Division of Mycobacterial and Respiratory Diseases Denver, Colorado
7 shared publications- Jakko van Ingen
Radboudumc Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands
6 shared publications - Kevin L. Winthrop
Oregon Health & Science University, School of Public Health, Portland, OR, USA; Oregon Health & Science University, School of Medicine, Portland, OR, USA
6 shared publications Kevin L. Winthrop
Division of Infectious Diseases, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA
5 shared publicationsClaire Andrejak
Department of Respiratory Diseases, Amiens-Picardie University Hospital, Amiens, France
4 shared publicationsJerry A. Nick
Department of Medicine, National Jewish Health, Denver, CO, USA
4 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
Amikacin Liposome Inhalation Suspension in Newly Diagnosed Mycobacterium avium Complex Lung Disease: A Phase 3b, Double-blind, Randomized Clinical Trial (ENCORE)
Rationale: Current recommended front-line multidrug therapy (MDT) for Mycobacterium avium complex lung disease (MACLD) produces suboptimal outcomes. Amikacin liposome inhalation suspension (ALIS) with MDT is approved for refractory MACLD; however, clinical trial evidence in newly diagnosed MACLD is lacking. Objectives: To evaluate efficacy and safety of ALIS with MDT in the phase 3b, randomized, double-blind, placebo-controlled superiority trial in adults newly diagnosed with MACLD who have not initiated antibiotics (ENCORE NCT04677569). Methods: Patients (N = 425) were randomized 1:1 to receive ALIS 590 mg (n = 213) or placebo (n = 212) plus azithromycin 250 mg and ethambutol 15 mg/kg once daily for 12 months. Primary endpoint was change from baseline to month 13 in Respiratory Symptom Score (RSS). Pre-specified secondary endpoints included culture conversion (CC) at clinically important timepoints, durable culture conversion (DCC), and safety. Results: Median age was 68.0 years, 62.8% were White, and 79.3% were female. Significantly greater improvements in RSS were observed in the ALIS versus comparator arm at 1 month post-treatment (month 13; LS mean change: 17.77 vs 14.66 points; treatment difference 3.11 points; P=0.0299), with improvements sustained at 3 months post-treatment (month 15; treatment arm difference 4.80 points; nominal P=0.0015). Significantly greater proportions of patients achieved CC by month 13 and DCC at month 15 in the ALIS arm versus comparator arm (82.4% vs 55.6% and 76.2% vs 47.6%, respectively; both P<0.0001). No new safety signals were observed. Conclusions: ALIS with MDT was superior to the comparator arm for improving respiratory symptoms and CC in patients newly diagnosed with MACLD.
- 30 September 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
Open AccessAmikacin Liposome Inhalation Suspension in Newly Diagnosed Mycobacterium avium Complex Lung Disease: A Phase 3b, Double-blind, Randomized Clinical Trial (ENCORE)
Rationale: Current recommended front-line multidrug therapy (MDT) for Mycobacterium avium complex lung disease (MACLD) produces suboptimal outcomes. Amikacin liposome inhalation suspension (ALIS) with MDT is approved for refractory MACLD; however, clinical trial evidence in newly diagnosed MACLD is lacking. Objectives: To evaluate efficacy and safety of ALIS with MDT in the phase 3b, randomized, double-blind, placebo-controlled superiority trial in adults newly diagnosed with MACLD who have not initiated antibiotics (ENCORE NCT04677569). Methods: Patients (N = 425) were randomized 1:1 to receive ALIS 590 mg (n = 213) or placebo (n = 212) plus azithromycin 250 mg and ethambutol 15 mg/kg once daily for 12 months. Primary endpoint was change from baseline to month 13 in Respiratory Symptom Score (RSS). Pre-specified secondary endpoints included culture conversion (CC) at clinically important timepoints, durable culture conversion (DCC), and safety. Results: Median age was 68.0 years, 62.8% were White, and 79.3% were female. Significantly greater improvements in RSS were observed in the ALIS versus comparator arm at 1 month post-treatment (month 13; LS mean change: 17.77 vs 14.66 points; treatment difference 3.11 points; P=0.0299), with improvements sustained at 3 months post-treatment (month 15; treatment arm difference 4.80 points; nominal P=0.0015). Significantly greater proportions of patients achieved CC by month 13 and DCC at month 15 in the ALIS arm versus comparator arm (82.4% vs 55.6% and 76.2% vs 47.6%, respectively; both P<0.0001). No new safety signals were observed. Conclusions: ALIS with MDT was superior to the comparator arm for improving respiratory symptoms and CC in patients newly diagnosed with MACLD.
- Top Cited PapersOpen Access
- 23 January 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 23 (4) , 536-547
Amikacin liposome inhalation suspension in newly diagnosed Mycobacterium avium complex lung disease (ARISE): a 6-month double-blind, active comparator trial
Rationale: Guidelines recommend amikacin liposome inhalation suspension (ALIS) for refractory Mycobacterium avium complex lung disease (MACLD) treatment, alongside other antibiotics. Efficacy of ALIS on microbiological endpoints and patient-reported outcomes (PROs) in the newly diagnosed MACLD population is unknown. Objectives: ARISE aimed to validate Quality of Life–Bronchiectasis Respiratory Domain (QOL-B RD) and Patient-Reported Outcomes Measurement Information System Short Form v1.0-Fatigue 7a (PROMIS F SF-7a) in patients treated for new/recurrent MACLD. We present treatment outcome results, including microbiological endpoints, PROs, and safety. Methods: Adults with noncavitary MACLD were randomized 1:1 to ALIS (590 mg) or empty liposome control (comparator), plus azithromycin (250 mg) and ethambutol (15 mg/kg) once daily for 6 months, then 1 month off treatment. Results: Of 99 patients, most had Mycobacterium intracellulare (43.4%) and/or M avium (32.3%) infections. Culture conversion with ALIS was achieved by 80.6% by month 6 (comparator, 63.9%) and 78.8% by month 7 (comparator, 47.1%; nominal P = .0010). Among patients achieving culture conversion by month 6, first negative culture defining conversion occurred at month 1 for 74.3% with ALIS (comparator, 46.7%). Mean QOL-B RD score through month 7 improved with ALIS versus plateauing with comparator after month 3; both arms showed improved PROMIS F SF-7a without between-arm difference. Positive correlations between culture conversion and improved QOL-B RD score were observed with ALIS. No ALIS-related serious adverse events or deaths were reported. Conclusions: More patients with newly diagnosed MACLD receiving 6 months of ALIS alongside a macrolide-based regimen achieved culture conversion by month 6 and month 7 numerically more rapidly versus comparator. No new safety signals were identified. Clinical trial registered with www.clinicaltrials.gov (NCT04677543).
- 23 January 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 23 (4) , 536-547
Top Cited PapersOpen AccessAmikacin liposome inhalation suspension in newly diagnosed Mycobacterium avium complex lung disease (ARISE): a 6-month double-blind, active comparator trial
Rationale: Guidelines recommend amikacin liposome inhalation suspension (ALIS) for refractory Mycobacterium avium complex lung disease (MACLD) treatment, alongside other antibiotics. Efficacy of ALIS on microbiological endpoints and patient-reported outcomes (PROs) in the newly diagnosed MACLD population is unknown. Objectives: ARISE aimed to validate Quality of Life–Bronchiectasis Respiratory Domain (QOL-B RD) and Patient-Reported Outcomes Measurement Information System Short Form v1.0-Fatigue 7a (PROMIS F SF-7a) in patients treated for new/recurrent MACLD. We present treatment outcome results, including microbiological endpoints, PROs, and safety. Methods: Adults with noncavitary MACLD were randomized 1:1 to ALIS (590 mg) or empty liposome control (comparator), plus azithromycin (250 mg) and ethambutol (15 mg/kg) once daily for 6 months, then 1 month off treatment. Results: Of 99 patients, most had Mycobacterium intracellulare (43.4%) and/or M avium (32.3%) infections. Culture conversion with ALIS was achieved by 80.6% by month 6 (comparator, 63.9%) and 78.8% by month 7 (comparator, 47.1%; nominal P = .0010). Among patients achieving culture conversion by month 6, first negative culture defining conversion occurred at month 1 for 74.3% with ALIS (comparator, 46.7%). Mean QOL-B RD score through month 7 improved with ALIS versus plateauing with comparator after month 3; both arms showed improved PROMIS F SF-7a without between-arm difference. Positive correlations between culture conversion and improved QOL-B RD score were observed with ALIS. No ALIS-related serious adverse events or deaths were reported. Conclusions: More patients with newly diagnosed MACLD receiving 6 months of ALIS alongside a macrolide-based regimen achieved culture conversion by month 6 and month 7 numerically more rapidly versus comparator. No new safety signals were identified. Clinical trial registered with www.clinicaltrials.gov (NCT04677543).
- Open Access
- 9 January 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (2) , 101357
Efficacy and safety of brensocatib in Japanese patients with non-cystic fibrosis bronchiectasis: Analysis of the ASPEN trial
- 9 January 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (2) , 101357
Open AccessEfficacy and safety of brensocatib in Japanese patients with non-cystic fibrosis bronchiectasis: Analysis of the ASPEN trial
- 6 November 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (1) , 2500400
Consensus on the management of refractory nontuberculous mycobacterial pulmonary disease
Background: Nontuberculous mycobacteria (NTM) are associated with chronic and challenging infections, particularly pulmonary disease (NTM-PD). While clinical guidelines provide treatment recommendations for the most common disease-causing species, they offer limited guidance on managing treatment failures. This study aims to develop a consensus-based decision-making framework for addressing treatment failure in NTM-PD. Methods: A panel of 16 international experts used the e-Delphi method to address gaps in NTM-PD management. Initial statements were derived from an open-ended questionnaire, supported by a prior systematic review. Iterative rounds of expert evaluation were conducted until a consensus was reached on treatment failure definitions, decision-making criteria, therapeutic strategies and supportive care measures. Results: Consensus defined treatment failure as the absence of culture conversion after 6 months of appropriate antimycobacterial therapy, while clinical and radiological deterioration were considered additional but non-mandatory criteria. Treatment intensification or de-escalation decisions were based on patient preferences, clinical status, comorbidities, disease severity, antibiotic tolerance, resistance patterns and previous treatment history. Treatment intensification highlighted the necessity for personalised multidrug antibiotic regimens. De-escalation strategies focus on delivering optimal, patient-centred supportive care while minimising pharmacological adverse effects, by opting for simplified antibiotic regimens, intermittent antibiotic courses for symptomatic control or the cessation of antimicrobial therapy. Conclusion: This study offers a structured approach to managing treatment failure in NTM-PD, addressing patient selection, treatment intensification, de-escalation and supportive care, while championing individualised strategies. Future research should concentrate on validating predictive factors for treatment response, refining therapeutic regimens and investigating host-directed therapies to enhance patient outcomes.
- 6 November 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (1) , 2500400
Consensus on the management of refractory nontuberculous mycobacterial pulmonary disease
Background: Nontuberculous mycobacteria (NTM) are associated with chronic and challenging infections, particularly pulmonary disease (NTM-PD). While clinical guidelines provide treatment recommendations for the most common disease-causing species, they offer limited guidance on managing treatment failures. This study aims to develop a consensus-based decision-making framework for addressing treatment failure in NTM-PD. Methods: A panel of 16 international experts used the e-Delphi method to address gaps in NTM-PD management. Initial statements were derived from an open-ended questionnaire, supported by a prior systematic review. Iterative rounds of expert evaluation were conducted until a consensus was reached on treatment failure definitions, decision-making criteria, therapeutic strategies and supportive care measures. Results: Consensus defined treatment failure as the absence of culture conversion after 6 months of appropriate antimycobacterial therapy, while clinical and radiological deterioration were considered additional but non-mandatory criteria. Treatment intensification or de-escalation decisions were based on patient preferences, clinical status, comorbidities, disease severity, antibiotic tolerance, resistance patterns and previous treatment history. Treatment intensification highlighted the necessity for personalised multidrug antibiotic regimens. De-escalation strategies focus on delivering optimal, patient-centred supportive care while minimising pharmacological adverse effects, by opting for simplified antibiotic regimens, intermittent antibiotic courses for symptomatic control or the cessation of antimicrobial therapy. Conclusion: This study offers a structured approach to managing treatment failure in NTM-PD, addressing patient selection, treatment intensification, de-escalation and supportive care, while championing individualised strategies. Future research should concentrate on validating predictive factors for treatment response, refining therapeutic regimens and investigating host-directed therapies to enhance patient outcomes.
- Open Access
- 1 October 2025
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 34 (178) , 250038
A systematic review of tetracyclines for nontuberculous mycobacteria: focus on rapidly growing mycobacteria
Background: The incidence and prevalence of disease caused by nontuberculous mycobacteria (NTM) are increasing globally, yet treatment regimens remain complex and often ineffective. Newer tetracyclines have shown promise as a potent therapeutic. In this systematic review, we assessed the evidence for the use of tetracyclines for the treatment of NTM disease, complemented by a narrative review of nonclinical data. Methods: Medline (PubMed) and Web of Science were searched from inception to February 2024 for clinical studies that assessed the safety, tolerability or efficacy of tetracyclines for NTM disease. Search results were screened against pre-defined inclusion and exclusion criteria. Nonclinical data were identified using a targeted literature search and are presented in a narrative synthesis. Results: A total of 89 citations were included, comprising 43 clinical studies (six prospective observational studies, 18 retrospective studies and 19 case series) and 46 nonclinical studies. Nonclinical studies demonstrated potent in vitro activity for tigecycline, omadacycline and eravacycline, particularly against rapidly growing mycobacteria (RGM). No randomised controlled trials (RCTs) were identified. Most clinical experience was for RGM (largely Mycobacterium abscessus) and supported the use of newer tetracyclines. Evidence for the treatment of slowly growing mycobacteria, particularly Mycobacterium avium complex, was more limited. Conclusions: There remains a significant unmet need for effective, well-tolerated therapies for the treatment of NTM, especially those that improve quality of life. Although tetracyclines have not been evaluated in RCTs, clinical evidence suggests that tetracyclines may contribute to the efficacy of combination regimens used to treat NTM disease and further RCTs are warranted.
- 1 October 2025
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 34 (178) , 250038
Open AccessA systematic review of tetracyclines for nontuberculous mycobacteria: focus on rapidly growing mycobacteria
Background: The incidence and prevalence of disease caused by nontuberculous mycobacteria (NTM) are increasing globally, yet treatment regimens remain complex and often ineffective. Newer tetracyclines have shown promise as a potent therapeutic. In this systematic review, we assessed the evidence for the use of tetracyclines for the treatment of NTM disease, complemented by a narrative review of nonclinical data. Methods: Medline (PubMed) and Web of Science were searched from inception to February 2024 for clinical studies that assessed the safety, tolerability or efficacy of tetracyclines for NTM disease. Search results were screened against pre-defined inclusion and exclusion criteria. Nonclinical data were identified using a targeted literature search and are presented in a narrative synthesis. Results: A total of 89 citations were included, comprising 43 clinical studies (six prospective observational studies, 18 retrospective studies and 19 case series) and 46 nonclinical studies. Nonclinical studies demonstrated potent in vitro activity for tigecycline, omadacycline and eravacycline, particularly against rapidly growing mycobacteria (RGM). No randomised controlled trials (RCTs) were identified. Most clinical experience was for RGM (largely Mycobacterium abscessus) and supported the use of newer tetracyclines. Evidence for the treatment of slowly growing mycobacteria, particularly Mycobacterium avium complex, was more limited. Conclusions: There remains a significant unmet need for effective, well-tolerated therapies for the treatment of NTM, especially those that improve quality of life. Although tetracyclines have not been evaluated in RCTs, clinical evidence suggests that tetracyclines may contribute to the efficacy of combination regimens used to treat NTM disease and further RCTs are warranted.
- Open Access
- 30 September 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (1) , e135-e145
The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus : From Laboratory Insights to Clinical Applications and the Case for Clinical Trials
Mycobacterium abscessus (Mab) is a highly drug-resistant non-tuberculous mycobacterium that presents major treatment challenges, particularly in individuals with structural lung disease. Although historically considered ineffective, β-lactam antibiotics have gained renewed attention due to advances in β-lactamase inhibition and cell wall biology. This review synthesizes more than a decade of work, including in vitro susceptibility studies, biochemical characterization of Mab's β-lactamase (BlaMab) and peptidoglycans synthesis, and published clinical cases supporting the potential role of β-lactam-based regimens. We detail the enzymatic pathways involved in peptidoglycan cross-linking and the dual inhibition of D,D- and L,D-transpeptidases by select β-lactams, as well as the functional impact of inhibiting BlaMab. Novel β-lactamase inhibitors such as durlobactam may further enhance β-lactam efficacy. By integrating laboratory insights with clinical experience, this review provides a comprehensive perspective and informs ongoing efforts to design clinical trials repurposing β-lactam/β-lactamase inhibitor combinations.
- 30 September 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (1) , e135-e145
Open AccessThe Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus : From Laboratory Insights to Clinical Applications and the Case for Clinical Trials
Mycobacterium abscessus (Mab) is a highly drug-resistant non-tuberculous mycobacterium that presents major treatment challenges, particularly in individuals with structural lung disease. Although historically considered ineffective, β-lactam antibiotics have gained renewed attention due to advances in β-lactamase inhibition and cell wall biology. This review synthesizes more than a decade of work, including in vitro susceptibility studies, biochemical characterization of Mab's β-lactamase (BlaMab) and peptidoglycans synthesis, and published clinical cases supporting the potential role of β-lactam-based regimens. We detail the enzymatic pathways involved in peptidoglycan cross-linking and the dual inhibition of D,D- and L,D-transpeptidases by select β-lactams, as well as the functional impact of inhibiting BlaMab. Novel β-lactamase inhibitors such as durlobactam may further enhance β-lactam efficacy. By integrating laboratory insights with clinical experience, this review provides a comprehensive perspective and informs ongoing efforts to design clinical trials repurposing β-lactam/β-lactamase inhibitor combinations.
- Open Access
- 1 July 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (7) , 1122-1124
Visualizing Pulmonary Mycobacteroides abscessus Infections with 11C Paraaminobenzoic Acid Positron Emission Tomography/Computed Tomography: A Journey, from Bench to Bedside
- 1 July 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (7) , 1122-1124
Open AccessVisualizing Pulmonary Mycobacteroides abscessus Infections with 11C Paraaminobenzoic Acid Positron Emission Tomography/Computed Tomography: A Journey, from Bench to Bedside
- Open Access
Management of Nontuberculous Mycobacterial Pulmonary Disease Refractory to Guideline-Based Therapy: A Systematic Review
Introduction: Managing patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) unresponsive to guideline-based therapy presents a significant clinical challenge. Limited treatment options and the complex nature of disease progression make therapeutic decision-making difficult. This study systematically reviewed the existing literature on management strategies and emerging therapeutic approaches for refractory NTM-PD. Methods: We systematically reviewed studies on NTM-PD treatment failure published from inception until 31 January 2024, examining associated factors, intensification strategies, and supportive measures. Twenty-five studies met the inclusion criteria, predominantly exhibiting retrospective observational methodology and focusing on pulmonary disease by Mycobacterium avium complex and Mycobacterium abscessus species. Findings were synthesised qualitatively due to the considerable heterogeneity in study design and outcomes. Results: Before treatment intensification or de-escalation, the impact of antibiotic treatment on health-related quality of life and microbiological factors, such as acquired resistance and changes in the pathogenic NTM, should be assessed. The presence of severe radiological findings at the beginning of treatment and a history of multiple antibiotic regimen modifications were associated with a lower chance of treatment success. Evidence regarding supportive interventions for treatment-refractory NTM-PD, such as nutritional counselling, respiratory rehabilitation, and psychosocial support, remains limited. Intermittent administration of intravenous antibiotics may be an additional strategy for symptom management. Depending on the causative NTM species, some antibiotic options have been explored for treatment intensification, although most of these are based on observational studies. Surgical resection remains an option for localised disease, although the risk of recurrence remains substantial in the case of preoperative positive culture. Novel therapeutic approaches remain under investigation as potential alternatives. Discussion: This systematic review underscores the complexity of managing refractory NTM-PD, highlighting the role of treatment intensification, symptom control, supportive measures and knowledge gaps. While no standardised approach exists, individualised strategies incorporating clinical, microbiological, and radiological factors remain essential for optimising patient outcomes.
Open AccessManagement of Nontuberculous Mycobacterial Pulmonary Disease Refractory to Guideline-Based Therapy: A Systematic Review
Introduction: Managing patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) unresponsive to guideline-based therapy presents a significant clinical challenge. Limited treatment options and the complex nature of disease progression make therapeutic decision-making difficult. This study systematically reviewed the existing literature on management strategies and emerging therapeutic approaches for refractory NTM-PD. Methods: We systematically reviewed studies on NTM-PD treatment failure published from inception until 31 January 2024, examining associated factors, intensification strategies, and supportive measures. Twenty-five studies met the inclusion criteria, predominantly exhibiting retrospective observational methodology and focusing on pulmonary disease by Mycobacterium avium complex and Mycobacterium abscessus species. Findings were synthesised qualitatively due to the considerable heterogeneity in study design and outcomes. Results: Before treatment intensification or de-escalation, the impact of antibiotic treatment on health-related quality of life and microbiological factors, such as acquired resistance and changes in the pathogenic NTM, should be assessed. The presence of severe radiological findings at the beginning of treatment and a history of multiple antibiotic regimen modifications were associated with a lower chance of treatment success. Evidence regarding supportive interventions for treatment-refractory NTM-PD, such as nutritional counselling, respiratory rehabilitation, and psychosocial support, remains limited. Intermittent administration of intravenous antibiotics may be an additional strategy for symptom management. Depending on the causative NTM species, some antibiotic options have been explored for treatment intensification, although most of these are based on observational studies. Surgical resection remains an option for localised disease, although the risk of recurrence remains substantial in the case of preoperative positive culture. Novel therapeutic approaches remain under investigation as potential alternatives. Discussion: This systematic review underscores the complexity of managing refractory NTM-PD, highlighting the role of treatment intensification, symptom control, supportive measures and knowledge gaps. While no standardised approach exists, individualised strategies incorporating clinical, microbiological, and radiological factors remain essential for optimising patient outcomes.
- Open Access
- 1 May 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (5) , 651-659
Comprehensive Management Algorithm for Mycobacterium avium Complex Pulmonary Disease in the Real-World Setting
The management of Mycobacterium avium complex pulmonary disease (MAC-PD) is challenging because of limited efficacy and frequent adverse events associated with standard treatments. The 2020 guidelines from the American Thoracic Society, European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases, and Infectious Diseases Society of America provide recommendations, but real-world adherence is often hindered by these issues, leading many patients to be unable to complete standard therapy. This review proposes a comprehensive management algorithm for MAC-PD, emphasizing multidisciplinary approaches and integrating nonantimicrobial management before, during, and after drug treatment to enhance patient outcomes. When a patient presents with chronic respiratory symptoms suggestive of nontuberculous mycobacteria, clinicians should follow a guideline-based approach to diagnosis, as diagnostic delays are common because of nonspecific symptoms. Proper evaluation should determine the disease phenotype (existence of cavitary lesions), as it influences treatment choices. Airway clearance, nutritional support, and management of underlying conditions are essential nonantimicrobial components. Regular outpatient monitoring helps detect disease progression and optimize treatment. Treatment strategies vary based on disease severity. For noncavitary nodular bronchiectatic disease, a thrice-weekly regimen is preferred because of better tolerability. Severe cases or those with cavitary forms may require daily treatment with additional aminoglycosides. Amikacin liposome inhalation suspension is recommended for patients not responding to standard regimens after 6 months. Recent research addresses drug intolerance, suggesting alternatives such as a two-drug regimen without rifamycin in certain cases. Consultation with nontuberculous mycobacteria specialists is advised for complex cases, particularly those with macrolide resistance or requiring surgical intervention. The algorithm emphasizes shared decision making, patient education, and family support to improve adherence and outcomes.
- 1 May 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (5) , 651-659
Open AccessComprehensive Management Algorithm for Mycobacterium avium Complex Pulmonary Disease in the Real-World Setting
The management of Mycobacterium avium complex pulmonary disease (MAC-PD) is challenging because of limited efficacy and frequent adverse events associated with standard treatments. The 2020 guidelines from the American Thoracic Society, European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases, and Infectious Diseases Society of America provide recommendations, but real-world adherence is often hindered by these issues, leading many patients to be unable to complete standard therapy. This review proposes a comprehensive management algorithm for MAC-PD, emphasizing multidisciplinary approaches and integrating nonantimicrobial management before, during, and after drug treatment to enhance patient outcomes. When a patient presents with chronic respiratory symptoms suggestive of nontuberculous mycobacteria, clinicians should follow a guideline-based approach to diagnosis, as diagnostic delays are common because of nonspecific symptoms. Proper evaluation should determine the disease phenotype (existence of cavitary lesions), as it influences treatment choices. Airway clearance, nutritional support, and management of underlying conditions are essential nonantimicrobial components. Regular outpatient monitoring helps detect disease progression and optimize treatment. Treatment strategies vary based on disease severity. For noncavitary nodular bronchiectatic disease, a thrice-weekly regimen is preferred because of better tolerability. Severe cases or those with cavitary forms may require daily treatment with additional aminoglycosides. Amikacin liposome inhalation suspension is recommended for patients not responding to standard regimens after 6 months. Recent research addresses drug intolerance, suggesting alternatives such as a two-drug regimen without rifamycin in certain cases. Consultation with nontuberculous mycobacteria specialists is advised for complex cases, particularly those with macrolide resistance or requiring surgical intervention. The algorithm emphasizes shared decision making, patient education, and family support to improve adherence and outcomes.
- 28 February 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (3) , e55-e56
Chronic Pulmonary Aspergillosis and Nontuberculous Mycobacterial Pulmonary Disease: Two Peas in a Pod
- 28 February 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (3) , e55-e56
Chronic Pulmonary Aspergillosis and Nontuberculous Mycobacterial Pulmonary Disease: Two Peas in a Pod